Humaneered anti-factor B antibody
This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof.
1. A method of reducing airway hyperresponsiveness (AHR) or airway inflammation comprising administering a composition comprising an engineered human anti-factor B antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier to an individual in need thereof, wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof comprises:
a) a V K -region comprising the amino acid sequence of SEQ ID NO:16 and a V H -region comprising the amino acid sequence of SEQ ID NO:17;
b) a V K -region comprising the amino acid sequence of SEQ ID NO:18 and a V H -region comprising the amino acid sequence of SEQ ID NO:19;
c) a V K -region comprising the amino acid sequence of SEQ ID NO:20 and a V H -region comprising the amino acid sequence of SEQ ID NO:21;
d) a V K -region comprising the amino acid sequence of SEQ ID NO:16 and a V H -region comprising the amino acid sequence of SEQ ID NO:35;
e) a V K -region comprising the amino acid sequence of SEQ ID NO:18 and a V H -region comprising the amino acid sequence of SEQ ID NO:36; or
f) a V K -region comprising the amino acid sequence of SEQ ID NO:20 and a V H -region comprising the amino acid sequence of SEQ ID NO:37,
wherein the antigen-binding fragment is selected from the group consisting of Fab', (Fab') 2 Fv, scFv, and diabodies and wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof reduces C3bBb complex formation in the individual.
2. The method of claim 1 , wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof is administered to the individual in an amount effective to measurably reduce AHR or airway inflammation in the animal as compared to before administration of the antibody or antigen-binding fragment thereof.
3. The method of claim 2 , wherein said AHR or airway inflammation is associated with a disease selected from the group consisting of asthma, chronic obstructive pulmonary disease (“COPD”), allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic pneumonia, emphysema, bronchitis, allergic bronchitis bronchiectasis, cystic fibrosis, tuberculosis, hypersensitivity pneumonitis, occupational asthma, sarcoid, reactive airway disease syndrome, interstitial lung disease, hyper-eosinophilic syndrome, rhinitis, sinusitis, exercise-induced asthma, pollution-induced asthma, cough variant asthma, parasitic lung disease, respiratory syncytial virus (“RSV”) infection, parainfluenza virus (“PIV”) infection, rhinovirus (“RV”) infection, and adenovirus infection.
4. The method of claim 2 , wherein the AHR or airway inflammation is associated with allergic inflammation.
5. The method of claim 2 , wherein the AHR or airway inflammation is associated with asthma.
6. The method of claim 2 , wherein the AHR or airway inflammation is associated with COPD.
7. A method comprising administering a composition comprising an engineered human anti-factor B antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier to an individual in need thereof, wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof comprises:
a) a V K -region comprising the amino acid sequence of SEQ ID NO:16 and a V H -region comprising the amino acid sequence of SEQ ID NO:17;
b) a V K -region comprising the amino acid sequence of SEQ ID NO:18 and a V H -region comprising the amino acid sequence of SEQ ID NO:19;
c) a V K -region comprising the amino acid sequence of SEQ ID NO:20 and a V H -region comprising the amino acid sequence of SEQ ID NO:21;
d) a V K -region comprising the amino acid sequence of SEQ ID NO:16 and a V H -region comprising the amino acid sequence of SEQ ID NO:35;
e) a V K -region comprising the amino acid sequence of SEQ ID NO:18 and a V H -region comprising the amino acid sequence of SEQ ID NO:36; or
f) V K -region comprising the amino acid sequence of SEQ ID NO:20 and a V H -region comprising the amino acid sequence of SEQ ID NO:37,
wherein the antigen-binding fragment is selected from the group consisting of Fab', (Fab') 2 Fv, scFv, and diabodies and wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof reduces C3bBb complex formation in the individual.
8. The method of claim 7 , wherein the antigen-binding fragment is a Fab'.
9. The method of claim 7 , wherein the antigen-binding fragment is a Fab'.
10. The method of claim 1 , wherein the engineered human antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (“K D ) between about 1.0×10 -8 M and about 1.0×10 -10 M.
11. The method of claim 10 , wherein the engineered human antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (”K D ) between about 3.0×10 -9 M and about 7.0×10 -9 M.
12. The method of claim 1 wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof further comprises a targeting ligand.
13. The method of claim 1 , further comprising administering an anti-inflammatory agent.
14. The method of claim 1 , wherein the individual is a human.
15. The method of claim 7 , wherein the engineered human antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (“K D ) between about 1.0×10 -8 M and about 1.010 -1 M.
16. The method of claim 15 , wherein the engineered human antibody or antigen-binding fragment thereof has an equilibrium dissociation constant (”K D ) between about 3.0×10 -9 M and about 7.0×10 -9 M.
17. The method of claim 7 , wherein the engineered human anti-factor B antibody or antigen-binding fragment thereof further comprises a targeting ligand.
18. The method of claim 7 , further comprising administering an anti-inflammatory agent.
19. The method of claim 7 , wherein the individual is a human.
20. The method of claim 7 , wherein the antigen-binding fragment is a Fab'.
21. The method of claim 7 , wherein the composition is formulated for administration by a route selected from the group consisting of oral, nasal, topical, inhalation, intratracheal, transdermal, rectal, and parenteral.
22. The method of claim 1 , wherein the composition is formulated for administration by a route selected from the group consisting of oral, nasal, topical, inhalation, intratracheal, transdermal, rectal, and parenteral.